Purpose:
ONO-9054 (Ono Pharmaceuticals, Osaka Japan) is a novel dual EP3/FP agonist that is currently in development for the treatment of ocular hypertension and glaucoma. The purpose of this study was to investigate the effect of ONO-9054 on aqueous humor dynamics in monkeys.

Methods:
Aqueous humor flow was measured with a fluorophotometer in 15 monkeys per group that received unilateral ocular administration of vehicle, timolol (5000 μg/mL), latanoprost (50 μg/mL) or ONO-9054 (3, 10, or 30 μg/mL). Outflow facility was determined using a two-level, constant pressure perfusion method in 10 monkeys per group that received unilateral ocular administration of latanoprost (50 μg/mL) or ONO-9054 (3, 10, or 30 μg/mL) in one eye and vehicle in the contralateral eye. Uveoscleral outflow was measured by perfusion the anterior chamber using FITC-labeled dextran in 8 monkeys per group that received unilateral ocular administration of latanoprost (50 μg/mL) or ONO-9054 (30 μg/mL) in one eye and vehicle in the contralateral eye.

Conclusions:
ONO-9054, a dual agonist for prostaglandin EP3 and FP receptors, increases both total outflow and uveoscleral outflow but not aqueous humor flow. This study demonstrates that ONO-9054 has dual action on aqueous outflow.